Cell and antibody therapies directed against surface molecules on B cells, e.g., CD19-targeting chimeric antigen receptor T cell therapy (CD19 CAR-T), are now standard treatments for patients with chemorefractory B cell acute lymphoblastic leukemias (B-ALL) and other B cell malignancies. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.